Get Quote: JNJ
Financials: Latest Results
Last year, Johnson & Johnson CEO Bill Weldon called 2009 one of the most challenging years in the company's history. 2010 hasn't been any easier.
Subscribe to Fortune Magazine
J&J has had to deal with 11 major FDA recalls in the past year, including a recent recall of leaky insulin cartridges. The company faces strict regulatory oversight at its McNeil plants the next five years under an agreement with the FDA. Regulators abroad are taking actions too: J&J's Acuvue and TruEye contact lenses were recalled in Europe and Asia last August due to manufacturing problems. Weldon insists that the company's problems are being addressed. --S.D. Is Johnson & Johnson a great company, or what?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Industry: Pharmaceuticals
|
Fortune 500+ Web app
Galleries and more
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rank # of Fortune 500 Companies | |
|---|---|
| New York | 57 |
| California | 53 |
| Texas | 51 |
| Company | Rank |
|---|---|
| Microsoft | 38 |
| Goldman Sachs | 54 |
| Intel | 56 |
| Company | 2010 $ (millions) |
|---|---|
| Exxon Mobil | $30,460.0 |
| AT&T | $19,864.0 |
| Chevron | $19,024.0 |
.
